Navigation Links
Fibrocell Science and Intrexon Expand Collaboration to Include Hypermobility-Type Ehlers-Danlos Syndrome

EXTON, Pa. and GERMANTOWN, Md., Jan. 13, 2014 /PRNewswire/ -- Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today an expansion of their Exclusive Channel Collaboration (ECC) to develop a treatment for Ehlers-Danlos syndrome hypermobility type (EDS-HT), a rare genetic disorder resulting in weakened connective tissue.

Fibrocell and Intrexon will endeavor to engineer autologous fibroblast cells genetically corrected to produce tenascin-X (TN-X), a protein that is deficient in the connective tissue of a subset of EDS-HT patients.  Patients with EDS-HT often experience significant musculoskeletal complications, including frequent joint dislocations, subluxations and early onset osteoarthritis.

Jouni Uitto, M.D., Ph.D., Chair of the Department of Dermatology and Cutaneous Biology at Thomas Jefferson University in Philadelphia, Pennsylvania, said the collaboration is a step toward addressing the unmet needs of EDS patients around the world.

"There are currently no therapies for hypermobility-type EDS," said Dr. Uitto. "Healthcare providers are only able to treat the severe symptoms of EDS, such as prescribing braces to improve joint stability and by assisting patients with the pain they experience.  The prospect of an actual treatment is wonderful news for these patients."

Fibrocell Chief Executive Officer David Pernock noted that the companies' evolving expertise and experience gained through the existing RDEB collaboration will be leveraged to accelerate EDS therapy research and development.

"Intrexon and Fibrocell have unique experience in protein replacement therapy using autologous fibroblasts as a delivery mechanism," said David Pernock, Fibrocell Science Chief Executive Officer. "Intrexon's UltraVector® technology has made it possible for Fibrocell to leverage the power of its autologous fibroblasts to address a host of unmet medical needs."

Using Fibrocell's autologous fibroblast technology platform and Intrexon's UltraVector® platform, the companies plan to genetically modify autologous fibroblasts to express TN-X. The goal is to employ the TN-X-expressing cells in the clinic, where they would be injected into EDS-HT patients at the disease sites – most likely lower limbs like knees, hips and feet, as well as the jaw – to correct connective tissue malfunction caused by deficient TN-X expression.  Fibrocell's technology led to the FDA-approved cell based autologous fibroblast product, azficel-T (LAVIV®).

"Fibrocell is unique in that it has identified, fostered and developed a unique method of harvesting and expanding human autologous fibroblasts ex vivo," said Samuel Broder, M.D., Chairman of Intrexon's Health Sector and former Director of the National Cancer Institute.

"We see vast potential for additional disease targets as we grow our collaborative relationship with Fibrocell.  Through our collaborations our goal is to develop wholly new classes of therapeutics for the treatment of multiple skin disorders with unmet medical needs that potentially affect millions worldwide," Dr. Broder said. 

Under terms of the expanded agreement, Intrexon will receive a technology access fee of $5 million in Fibrocell common stock valued at the closing price on January 9, 2014 of $4.88.  Other aspects of the agreement duplicate the terms related to the existing collaboration pertaining to RDEB and the new class of therapeutics the companies are developing for morphea, cutaneous eosinophilias, and psoriasis.

About Fibrocell Science, Inc.
Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs. Based on its proprietary autologous fibroblast technology, Fibrocell is pursuing breakthrough medical applications of azficel-T for restrictive burn scarring and vocal cord scarring.  The company's collaboration with Intrexon Corporation (NYSE: XON), a leader in synthetic biology, includes using genetically-modified fibroblasts for treating orphan skin diseases for which there are no currently approved products and exploring the localized treatment of the most common autoimmune skin disease, moderate-to-severe psoriasis.  Fibrocell's collaboration with UCLA—focusing on skin-derived stem cells and more efficient ways to convert skin cells to other cell types—holds potential for future discovery and development of autologous cellular therapeutics. For additional information, visit

About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy and the Environment to create biologically-based products that improve the quality of life and the health of the planet.  Through the company's proprietary UltraVector® platform, Intrexon provides its partners with industrial-scale design and development of complex biological systems.  The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells.  We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more

About UltraVector®
UltraVector® is one of Intrexon's proprietary technology platforms for the design, creation, modification, and regulation of complex gene programs and cellular systems at commercial scale.

Intrexon, UltraVector, and Better DNA are trademarks of Intrexon and/or its affiliates.  Other names may be trademarks of their respective owners.

Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements.  Forward-looking statements include, without limitation, the ability of Fibrocell and Intrexon to engineer autologous fibroblast cells genetically corrected to produce TN-X and to develop wholly new classes of therapeutics for the treatment of skin disorders with unmet medical needs. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results.

For more information, contact:

Fibrocell Contact:
Greg Weaver
Chief Financial Officer
Tel: +1 (484) 713-6000

Intrexon Corporation Contact:
Marie Rossi, Ph.D.
Manager, Technical Communications
Tel: +1 (301) 556-9944


SOURCE Intrexon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Science Magazine: Cancer Immunotherapy is the Medical Breakthrough of 2013; The CBCD Highlights the Link between Immunotherapy and Microcompetition
2. BioForce NanoSciences Adds Sixth Continent to Export List
3. Bayer CropScience to Share Insights on Unlocking New Canola Opportunities
4. Bayer CropScience Announces Darrin Dodds as the 2014 Extension Cotton Specialist of the Year
5. Capsugel’s Bend Research to Present New Processes for Flu Vaccine and Other Science Advancements at Upcoming Industry Meetings
6. A Unique Collaboration of Life Science Leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, has formed Triphase Accelerator Corporation to be an Oncology Development Accele
7. Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept
8. Sangamo BioSciences Announces Conference Call And Webcast To Discuss Global Collaboration with Biogen Idec to Develop Treatments for Hemoglobinopathies
9. Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research
10. TwinLink Technology from Bayer CropScience Now Available for 2014 Growing Season in FiberMax and Stoneville Cotton Varieties
11. Bayer CropScience Offers Seven New Varieties for 2014, Four with GlyTol LibertyLink TwinLink Technology for Weed and Insect Control
Post Your Comments:
(Date:10/13/2015)... ... , ... Proove Biosciences, a commercial and research leader ... Keck Medicine of the University of Southern California (USC) Pain Center to ... Research Clinical Objectives Linking Genotypic and Phenotypic Association with Pain Outcomes) is one ...
(Date:10/12/2015)... Ga. , Oct.12, 2015  MiMedx Group, Inc. ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the ... complaint which had been filed against the Company has ... H. Petit , Chairman and CEO, stated, "As we ...
(Date:10/12/2015)... 12, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) ... in developing and commercializing novel treatments in oncology, endocrinology ... Dennis Turpin , the Company,s former Senior Vice President, ... Quebec City office.  ... Executive Officer of the Company commented, "After a comprehensive ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... ... today that Dr. Srini Srinivasan, has joined the firm as a Premier Expert ... professional stature enable them to bring extraordinary value to the company's clients. ...
Breaking Biology Technology:
(Date:10/1/2015)... Oct. 1, 2015  Biometrics includes diverse set ... body characteristics, such as fingerprints, eye retinas, facial ... of biometrics technology has been constantly increasing in ... five years. In addition to the most prominent ... recognition, other means of biometric authentication are rapidly ...
(Date:9/30/2015)... NEW YORK , Sept. 30, 2015  The global ... $10,025 billion for 2015. So says a new report on ... and diabetes management segment dominate the market, followed by continuous ... research publisher. Kalorama reports on the market for these products in ... .  ...
(Date:9/28/2015)... , Sept. 28, 2015 CLEAR, ... that its expedited traveler service is coming ... transforms travel, bringing a frictionless experience, serious ... "CLEAR offers our travelers an ... service," said Jim Smith , Executive ...
Breaking Biology News(10 mins):